T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma
Sponsor: Bristol-Myers Squibb
A EARLY_PHASE1 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 15 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Oct 2023 — Jun 2024 [monthly]
Completed EARLY_PHASE1
-
Apr 2023 — Oct 2023 [monthly]
Completed EARLY_PHASE1
▶ Show 10 earlier versions
-
Jan 2021 — Apr 2023 [monthly]
Completed EARLY_PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2019 — Feb 2020 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Dec 2018 — Jun 2019 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jan 2018 [monthly]
Recruiting EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- High Impact Clinical Research Support Program
- M.D. Anderson Cancer Center
- Stand Up To Cancer
For direct contact, visit the study record on ClinicalTrials.gov .